Association of left ventricular diastolic dysfunction with inflammatory activity, renal dysfunction, and liver-related mortality in patients with cirrhosis and ascites.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
medline:
25
3
2024
pubmed:
25
3
2024
entrez:
25
3
2024
Statut:
aheadofprint
Résumé
Left ventricular diastolic dysfunction (LVDD) is the predominant cardiac abnormality in cirrhosis. We investigated the association of LVDD with systemic inflammation and its impact on renal function, occurrence of hepatorenal syndrome (HRS) and survival in patients with cirrhosis and ascites. We prospectively enrolled 215 patients with cirrhosis and ascites. We evaluated the diagnosis and grading of LVDD by Doppler echocardiography, inflammatory markers, systemic hemodynamics, vasoactive factors, radioisotope-assessed renal function and blood flow, HRS development and liver-related mortality. LVDD was diagnosed in 142 (66%) patients [grade 2/3: n = 61 (43%)]. Serum lipopolysaccharide-binding protein (LBP), plasma renin activity (PRA) and glomerular filtration rate (GFR) were independently associated with the presence of grade 2/3 LVDD and the severity of diastolic dysfunction. Serum tumor necrosis factor-α, cardiac output and plasma noradrenaline were also independently associated with the presence of grade 2/3 LVDD. The diastolic function marker E/e' was strongly correlated with serum LBP (r = 0.731; P < 0.001), PRA (r = 0.714; P < 0.001) and GFR (r = -0.609; P < 0.001) among patients with LVDD. The 5-year risk of HRS development and death was significantly higher in patients with grade 2/3 LVDD compared to those with grade 1 (35.5 vs. 14.4%; P = 0.01 and 53.3 vs. 28.2%; P = 0.03, respectively). The occurrence and severity of LVDD in patients with cirrhosis and ascites is closely related to inflammatory activity. Advanced LVDD is associated with baseline circulatory and renal dysfunction, favoring HRS development, and increased mortality.
Identifiants
pubmed: 38526935
doi: 10.1097/MEG.0000000000002762
pii: 00042737-990000000-00332
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008; 57:268–278.
Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015; 63:1272–1284.
Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int 2018; 38:570–580.
Liu H, Naser JA, Lin G, Lee SS. Cardiomyopathy in cirrhosis: from pathophysiology to clinical care. JHEP Rep 2023; 6:100911.
Stundiene I, Sarnelyte J, Norkute A, Aidietiene S, Liakina V, Masalaite L, et al. Liver cirrhosis and left ventricle diastolic dysfunction: systematic review. World J Gastroenterol 2019; 25:4779–4795.
Ruiz-del-Árbol L, Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol 2015; 21:11502–11521.
Liu H, Nguyen HH, Yoon KT, Lee SS. Pathogenic mechanisms underlying cirrhotic cardiomyopathy. Front Netw Physiol 2022; 2:849253.
Karagiannakis DS, Vlachogiannakos J, Anastasiadis G, Vafiadis-Zouboulis I, Ladas SD. Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia. Dig Dis Sci 2013; 58:3029–3036.
Cholongitas E, Goulis I, Pagourelias E, Birtsou C, Ioannidou M, Ioannidou M, et al. Diastolic dysfunction is associated with low urinary sodium excretion in patients with decompensated cirrhosis. Ann Hepatol 2016; 15:745–751.
Premkumar M, Devurgowda D, Vyas T, Shasthry SM, Khumuckham JS, Goyal R, et al. Left ventricular diastolic dysfunction is associated with renal dysfunction, poor survival and low health related quality of life in cirrhosis. J Clin Exp Hepatol 2019; 9:324–333.
Ruíz-del-Árbol L, Achécar L, Serradilla R, Rodríguez-Gandía MA, Rivero M, Garrido E, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. Hepatology 2013; 58:1732–1741.
Behera MK, Swain SN, Sahu MK, Behera GK, Mishra D, Narayan J, et al. Diastolic dysfunction is a predictor of poor survival in patients with decompensated cirrhosis. Int J Hepatol 2021; 2021:5592376.
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10:165–193.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. J Am Soc Echocardiogr 2005; 18:1440–1463.
Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56:1310–1318.
Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 2015; 64:531–537.
Kalambokis GN, Christaki M, Tsiakas I, Despotis G, Fillipas-Ntekouan S, Fotopoulos A, et al. Conversion of propranolol to carvedilol improves renal perfusion and outcome in patients with cirrhosis and ascites. J Clin Gastroenterol 2021; 55:721–729.
Kalambokis GN, Chouliara N, Tsiakas I, Filippas-Ntekuan S, Christaki M, Despotis G, et al. Impact of continued alcohol use on liver-related outcomes of alcohol-associated cirrhosis: a retrospective study of 440 patients. Eur J Gastroenterol Hepatol 2024; 36:89–96.
Debernardi Venon W, Lo Pumo S, Imperatrice B, Giorgi M, Righi D, Fonio P, et al. Transjugular intrahepatic portosystemic shunt in refractory ascites: clinical impact of left ventricular diastolic dysfunction. Eur J Gastroenterol Hepatol 2021; 33 (1S Suppl 1):e464–e470.
Nazar A, Guevara M, Sitges M, Terra C, Solà E, Guigou C, et al. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol 2013; 58:51–57.
Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999; 180:1584–1589.
Rozenberg S, Besse S, Brisson H, Jozefowicz E, Kandoussi A, Mebazaa A, et al. Endotoxin-induced myocardial dysfunction in senescent rats. Crit Care 2006; 10:R124.
Sturgess DJ, Morrison S, Haluska B, Gobe GC, Jones MA, Volante S, et al. Left ventricular impaired relaxation and interstitial myocarditis identified in sepsis-associated cardiac dysfunction: use of a rodent model. Med Sci Monit 2021; 27:e929512.
Sciarretta S, Paneni F, Palano F, Chin D, Tocci G, Rubattu S, et al. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 2009; 116:467–477.
Wu CK, Lee JK, Chiang FT, Yang CH, Huang SW, Hwang JJ, et al. Plasma levels of tumor necrosis factor-α and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase. Crit Care Med 2011; 39:984–992.
Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva AP, Valente J, et al. Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver Int 2013; 33:1158–1165.
Jia G, Aroor AR, Hill MA, Sowers JR. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension 2018; 72:537–548.
Gimelli A, Liga R, Avogliero F, Coceani M, Marzullo P. Relationships between left ventricular sympathetic innervation and diastolic dysfunction: the role of myocardial innervation/perfusion mismatch. J Nucl Cardiol 2016; 25:1101–1109.
McGhie AI, Corbett JR, Akers MS, Kulkarni P, Sills MN, Kremers M, et al. Regional cardiac adrenergic function using I-123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction. Am J Cardiol 1991; 67:236–242.
Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000; 141:1901–1904.
Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59:105–110.
Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42:439–447.
Schneider H, Berliner D, Stockhoff L, Reincke M, Mauz JB, Meyer B, et al. Diastolic dysfunction is associated with cardiac decompensation after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis. United European Gastroenterol J 2023; 11:837–851.
Bi S, Jiang Y, Zhao W, Niu X, Liu X, Jing X. The predictive value of revised diastolic dysfunction in outcomes of liver transplantation: a propensity score matching analysis. Front Surg 2023; 9:1072908.
Karagiannakis DS, Vlachogiannakos J, Anastasiadis G, Vafiadis-Zouboulis I, Ladas SD. Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis. Hepatol Int 2014; 8:588–594.
Lee SK, Song MJ, Kim SH, Ahn HJ. Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis. Clin Mol Hepatol 2018; 24:409–416.
Alexopoulou A, Papatheodoridis G, Pouriki S, Chrysohoou C, Raftopoulos L, Stefanadis C, et al. Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. Transpl Int 2012; 25:1174–1181.
Merli M, Calicchia A, Ruffa A, Pellicori P, Riggio O, Giusto M, et al. Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Eur J Intern Med 2013; 24:172–176.
Cesari M, Frigo AC, Tonon M, Angeli P. Cardiovascular predictors of death in patients with cirrhosis. Hepatology 2018; 68:215–223.
Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva AP, Valente J, et al. Left atrial function is impaired in cirrhosis: a speckle tracking echocardiographic study. Hepatol Int 2014; 8:146–153.